Jason Rhodes Sells 480,240 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 480,240 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $22.79, for a total transaction of $10,944,669.60. Following the completion of the transaction, the director directly owned 875,912 shares of the company’s stock, valued at $19,962,034.48. This trade represents a 35.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

DYN opened at $24.27 on Friday. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $25.00. The company has a fifty day simple moving average of $19.12 and a 200 day simple moving average of $18.31. The stock has a market cap of $4.01 billion, a P/E ratio of -7.54 and a beta of 1.06.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same period in the prior year, the business earned ($1.05) EPS. On average, research analysts expect that Dyne Therapeutics, Inc. will post -3.02 EPS for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in DYN. AQR Capital Management LLC bought a new position in shares of Dyne Therapeutics in the first quarter valued at $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Dyne Therapeutics by 5.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock worth $597,000 after acquiring an additional 2,886 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Dyne Therapeutics by 58.2% during the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after acquiring an additional 366,183 shares in the last quarter. Caxton Associates LLP acquired a new stake in Dyne Therapeutics in the first quarter valued at $157,000. Finally, Creative Planning lifted its stake in Dyne Therapeutics by 23.8% in the second quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after acquiring an additional 2,797 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a report on Friday, May 15th. Sanford C. Bernstein lifted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. TD Cowen started coverage on shares of Dyne Therapeutics in a report on Friday, June 26th. They issued a “buy” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.